Results 81 to 90 of about 1,426 (171)

The association of race with thyroid eye disease presentation and outcomes

Frontiers in Ophthalmology
IntroductionClassification of thyroid eye disease (TED) is largely based on guidelines developed in Europe and North America. Few studies have investigated the presentation and treatment of TED in Black populations.
Diane Wang, Diane Wang, Diane Wang, Charlotte Marous, Charlotte Marous, Charlotte Marous, Pelin Celiker, Wenyu Deng, Wenyu Deng, Eva Kristoferson, Ali Elsayed, Roman Shinder, Roman Shinder, Roman Shinder, Nickisa Hodgson, Nickisa Hodgson   +15 more
doaj   +1 more source

Correlation of Objective Ocular Alignment and Subjective Diplopia After Teprotumumab in Patients With Thyroid Eye Disease (TED)

Teprotumumab, an insulin-like growth factor one (IGF-1) antagonist improved proptosis and diplopia in patients with thyroid eye disease (TED). Prior clinical trials documented subjective improvement in diplopia in study subjects who received teprotumumab,
Tejus Pradeep; Taylor Linaburg; Cory Shoshany; Clare Teng; Kevin Zhang; Yuanyuan Chen; Cesar Briceno; Madhura Tamhankar
core  

Supplementary Material for: Severe Hyperglycemia with Teprotumumab for Treatment of Thyroid Eye Disease

Introduction: Thyroid eye disease (TED) is a rare condition involving autoimmune-mediated inflammation of the orbit and periocular structures, which can result in many debilitating symptoms.
Barrientez B. (18001288), Cottom S. (18001285), Melson A. (18001291)   +2 more
core   +1 more source

Teprotumumab (Tepezza)-Related Hyperglycemia is Associated With Baseline Glycemic Status in Thyroid Eye Disease

Teprotumumab (Tepezza) is an insulin-like growth factor 1 receptor antagonist that was recently approved for the treatment of Thyroid Eye Disease (TED), a potentially sight-threatening and debilitating orbital inflammatory disease.
Tracy Lang; Aaron Rael; Kristen Park; Jessica Chang; Sandy Zhang-Nunes
core  

A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface

, 2022
Teprotumumab, a monoclonal antibody that blocks the insulin-like growth factor-1 receptor, has recently been approved by the US Food and Drug Administration (FDA) for the treatment of thyroid eye disease (TED).
Shoaib Ugradar, MD; Andrea L. Kossler, MD; Raymond Douglas, MD, PhD; Kimberly Cockerham, MD
core  

Rapidly progressive cognitive decline and drug-induced encephalopathy secondary to teprotumumab for thyroid eye disease: a case report and narrative literature review

Frontiers in Immunology
BackgroundTeprotumumab, a fully human monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), is an approved targeted therapy for thyroid eye disease (TED). Teprotumumab-associated encephalopathy is an extremely rare but potentially
Zhi-Juan Cheng, Shi-Xian Zhou, Zi-Ying He, Ze-Fang Deng, Chuan Zeng, Wei-Ping Chen, Jiang-Long Tu   +6 more
doaj   +1 more source

Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm

Therapeutics and Clinical Risk Management, 2019
Yao Wang,1 Amy Patel,1 Raymond S Douglas1,2 1Department of Surgery, Division of Ophthalmology, Cedars Sinai Medical Center, Los Angeles, CA, USA; 2State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou ...
Wang Y, Patel A, Douglas RS
doaj  

Teprotumumab Effect on Proptosis, Diplopia and Quality of Life in Active Thyroid Eye Disease (TED) (Video)

, 2020
Active thyroid eye disease (TED), a progressive, autoimmune condition, produces retro-orbital inflammation/tissue expansion. Patients present with ocular pain, redness, and swelling.
Jade Schiffman; Rosa Tang; George Kahaly; Terry Smith; Saba Sile; Elizabeth Thompson; Thomas Vescio; Jeffrey Sherman; Raymond Douglas
core  

Teprotumumab Induced Adrenal Insufficiency: A Case Report

We report a case of adrenal insufficiency in a patient who had been receiving teprotumumab infusions for the treatment of thyroid eye disease.
Justin Youn; Douglas Van Putten; Eman Hawy
core  

Immune checkpoints: new insights into the pathogenesis of thyroid eye disease

Frontiers in Immunology
Thyroid eye disease (TED) is a disfiguring autoimmune disease characterized by changes in the orbital tissues and is caused by abnormal thyroid function or thyroid-related antibodies. It is the ocular manifestation of Graves’ disease.
Xingyi Shu, Yuchao Shao, Yuqing Chen, Chengcheng Zeng, Xiao Huang, Ruili Wei   +5 more
doaj   +1 more source